Correlation Between Connect Biopharma and Xilio Development

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Connect Biopharma and Xilio Development at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Connect Biopharma and Xilio Development into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Connect Biopharma Holdings and Xilio Development, you can compare the effects of market volatilities on Connect Biopharma and Xilio Development and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Connect Biopharma with a short position of Xilio Development. Check out your portfolio center. Please also check ongoing floating volatility patterns of Connect Biopharma and Xilio Development.

Diversification Opportunities for Connect Biopharma and Xilio Development

-0.39
  Correlation Coefficient

Very good diversification

The 3 months correlation between Connect and Xilio is -0.39. Overlapping area represents the amount of risk that can be diversified away by holding Connect Biopharma Holdings and Xilio Development in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Xilio Development and Connect Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Connect Biopharma Holdings are associated (or correlated) with Xilio Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Xilio Development has no effect on the direction of Connect Biopharma i.e., Connect Biopharma and Xilio Development go up and down completely randomly.

Pair Corralation between Connect Biopharma and Xilio Development

Given the investment horizon of 90 days Connect Biopharma Holdings is expected to generate 0.89 times more return on investment than Xilio Development. However, Connect Biopharma Holdings is 1.13 times less risky than Xilio Development. It trades about 0.03 of its potential returns per unit of risk. Xilio Development is currently generating about 0.03 per unit of risk. If you would invest  102.00  in Connect Biopharma Holdings on August 24, 2024 and sell it today you would lose (2.99) from holding Connect Biopharma Holdings or give up 2.93% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Connect Biopharma Holdings  vs.  Xilio Development

 Performance 
       Timeline  
Connect Biopharma 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Connect Biopharma Holdings are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Connect Biopharma sustained solid returns over the last few months and may actually be approaching a breakup point.
Xilio Development 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Xilio Development are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Xilio Development displayed solid returns over the last few months and may actually be approaching a breakup point.

Connect Biopharma and Xilio Development Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Connect Biopharma and Xilio Development

The main advantage of trading using opposite Connect Biopharma and Xilio Development positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Connect Biopharma position performs unexpectedly, Xilio Development can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xilio Development will offset losses from the drop in Xilio Development's long position.
The idea behind Connect Biopharma Holdings and Xilio Development pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Complementary Tools

Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk